T. Iijima

发表

Acute effect of add‐on therapy with tofogliflozin, a sodium glucose co‐transporter 2 inhibitor, on 24‐hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase‐4 inhibitors

Y. Aso, T. Jojima, T. Tomaru, 2021, International journal of clinical practice.

Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.

Y. Aso, T. Jojima, T. Kogai, 2021, International journal of cardiology.

Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.

Y. Aso, T. Jojima, T. Tomaru, 2020, Journal of diabetes and its complications.

Synergistic effects of liver fibrosis and sarcopenia on endothelial dysfunction and arterial stiffness in patients with type 2 diabetes

Y. Aso, T. Jojima, T. Tomaru, 2022, International journal of cardiology. Heart & vasculature.

Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report

Y. Aso, T. Jojima, T. Kogai, 2019, Journal of Medical Case Reports.

Concurrent variant type 3 autoimmune polyglandular syndrome and pulmonary arterial hypertension in a Japanese woman.

Kunihiro Suzuki, K. Yanagi, Y. Aso, 2018, Endocrine journal.

Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells.

Kunihiro Suzuki, Y. Aso, T. Jojima, 2017, Diabetes research and clinical practice.

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Kunihiro Suzuki, Y. Aso, T. Jojima, 2016, Diabetology & Metabolic Syndrome.

Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.

Y. Aso, T. Jojima, T. Tomaru, 2020, The American journal of the medical sciences.

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes

K. Hara, Y. Aso, T. Jojima, 2015, Endocrine.

Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease

Y. Aso, T. Jojima, T. Tomaru, 2021, Journal of Investigative Medicine.

The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes.

Kunihiro Suzuki, Y. Aso, T. Jojima, 2013, Translational research : the journal of laboratory and clinical medicine.

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.

Kunihiro Suzuki, K. Yanagi, Y. Aso, 2017, Atherosclerosis.

Relationship between reduced heart rate variability and increased arterial stiffness evaluated by the cardio-ankle vascular index in people with type 2 diabetes

Y. Aso, T. Jojima, T. Tomaru, 2022, Diabetology International.

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Kunihiro Suzuki, Y. Aso, T. Jojima, 2018, Diabetes, obesity & metabolism.

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Y. Aso, T. Jojima, K. Shimomura, 2019, International journal of clinical practice.

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.

Kunihiro Suzuki, Y. Aso, T. Jojima, 2015, Diabetes research and clinical practice.

Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients.

Chie Aoki, Y. Hattori, A. Tomizawa, 2011, Endocrine journal.

Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.

Y. Aso, T. Jojima, T. Tomaru, 2021, Journal of diabetes and its complications.

Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet–Fed Mice

K. Tobe, Y. Aso, T. Jojima, 2022, International journal of molecular sciences.

No Negative Impact of a National State of Emergency by COVID-19 Outbreak on Hemoglobin A1c Levels in Patients With Type 2 Diabetes Living in Semi-Rural Japan

Y. Aso, T. Jojima, T. Tomaru, 2021, The American Journal of the Medical Sciences.

Symptomatic hypocalcemia after treatment for hyperthyroidism in a woman with chromosome 22q11.2 deletion syndrome complicated by Graves' disease: longitudinal changes in the number of subsets of CD4 and CD8 lymphocytes after thyroidectomy.

Y. Aso, T. Jojima, T. Kogai, 2021, Endocrine journal.

Effects of treatment with methimazole on circulating CD4+ and CD8+ T cells positive for programed cell death protein‐1 and on subsets of CD4+ T cells in untreated hyperthyroid patients with Graves' disease

Y. Aso, T. Jojima, T. Tomaru, 2022, Clinical endocrinology.

Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report.

Y. Aso, T. Jojima, T. Kogai, 2020, European journal of endocrinology.

Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance.

Y. Aso, T. Jojima, T. Kogai, 2022, Endocrine journal.

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma

Y. Aso, T. Jojima, K. Shimomura, 2019, International journal of molecular sciences.

Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe Obesity

K. Kojima, Y. Aso, T. Jojima, 2022, Internal medicine.

A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation

Y. Aso, T. Jojima, T. Kogai, 2020, Clinical case reports.

Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor.

T. Jojima, T. Kogai, T. Iijima, 2023, Journal of diabetes and its complications.

Patients with diabetes and obesity exhibit characteristics in eating and coping behaviors and personality traits

Norio Sugawara, T. Jojima, T. Iijima, 2024, Diabetology International.

Y. Aso, T. Jojima, T. Iijima, 2021, International journal of clinical practice.